Browse RPLP0

Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Localized in cytoplasmic mRNP granules containing untranslated mRNAs (PubMed:19188445, PubMed:17289661).
Domain PF00466 Ribosomal protein L10
Function

Ribosomal protein P0 is the functional equivalent of E.coli protein L10.

> Gene Ontology
 
Biological Process GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay
GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0002181 cytoplasmic translation
GO:0006364 rRNA processing
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006413 translational initiation
GO:0006612 protein targeting to membrane
GO:0006613 cotranslational protein targeting to membrane
GO:0006614 SRP-dependent cotranslational protein targeting to membrane
GO:0007589 body fluid secretion
GO:0007595 lactation
GO:0010035 response to inorganic substance
GO:0010269 response to selenium ion
GO:0014074 response to purine-containing compound
GO:0016072 rRNA metabolic process
GO:0019058 viral life cycle
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0019439 aromatic compound catabolic process
GO:0022613 ribonucleoprotein complex biogenesis
GO:0030879 mammary gland development
GO:0032941 secretion by tissue
GO:0034470 ncRNA processing
GO:0034655 nucleobase-containing compound catabolic process
GO:0042254 ribosome biogenesis
GO:0044033 multi-organism metabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0045047 protein targeting to ER
GO:0046683 response to organophosphorus
GO:0046700 heterocycle catabolic process
GO:0048732 gland development
GO:0050878 regulation of body fluid levels
GO:0051591 response to cAMP
GO:0070670 response to interleukin-4
GO:0070972 protein localization to endoplasmic reticulum
GO:0071320 cellular response to cAMP
GO:0071353 cellular response to interleukin-4
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0072599 establishment of protein localization to endoplasmic reticulum
GO:0072657 protein localization to membrane
GO:0090150 establishment of protein localization to membrane
GO:1901361 organic cyclic compound catabolic process
GO:1904400 response to Thyroid stimulating hormone
GO:1904401 cellular response to Thyroid stimulating hormone
GO:1904627 response to phorbol 13-acetate 12-myristate
GO:1904628 cellular response to phorbol 13-acetate 12-myristate
Molecular Function GO:0003735 structural constituent of ribosome
GO:0019843 rRNA binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0070180 large ribosomal subunit rRNA binding
Cellular Component GO:0005840 ribosome
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0015934 large ribosomal subunit
GO:0022625 cytosolic large ribosomal subunit
GO:0022626 cytosolic ribosome
GO:0030055 cell-substrate junction
GO:0030425 dendrite
GO:0030684 preribosome
GO:0030687 preribosome, large subunit precursor
GO:0035770 ribonucleoprotein granule
GO:0036464 cytoplasmic ribonucleoprotein granule
GO:0044391 ribosomal subunit
GO:0044445 cytosolic part
> KEGG and Reactome Pathway
 
KEGG hsa03010 Ribosome
Reactome R-HSA-157279: 3' -UTR-mediated translational regulation
R-HSA-72737: Cap-dependent Translation Initiation
R-HSA-1643685: Disease
R-HSA-156842: Eukaryotic Translation Elongation
R-HSA-72613: Eukaryotic Translation Initiation
R-HSA-72764: Eukaryotic Translation Termination
R-HSA-72689: Formation of a pool of free 40S subunits
R-HSA-72706: GTP hydrolysis and joining of the 60S ribosomal subunit
R-HSA-74160: Gene Expression
R-HSA-5663205: Infectious disease
R-HSA-168254: Influenza Infection
R-HSA-168255: Influenza Life Cycle
R-HSA-168273: Influenza Viral RNA Transcription and Replication
R-HSA-156827: L13a-mediated translational silencing of Ceruloplasmin expression
R-HSA-6791226: Major pathway of rRNA processing in the nucleolus and cytosol
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-392499: Metabolism of proteins
R-HSA-975957: Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
R-HSA-975956: Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
R-HSA-927802: Nonsense-Mediated Decay (NMD)
R-HSA-156902: Peptide chain elongation
R-HSA-1799339: SRP-dependent cotranslational protein targeting to membrane
R-HSA-2408522: Selenoamino acid metabolism
R-HSA-2408557: Selenocysteine synthesis
R-HSA-72766: Translation
R-HSA-192823: Viral mRNA Translation
R-HSA-72312: rRNA processing
R-HSA-8868773: rRNA processing in the nucleus and cytosol
Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RPLP0 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RPLP0 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.55 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RPLP0 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1730.553
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.110.982
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3750.919
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2650.6
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1530.959
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7970.84
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1230.849
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2650.93
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0021
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0320.992
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1770.974
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0410.659
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RPLP0 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RPLP0. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RPLP0. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RPLP0.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RPLP0. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RPLP0 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RPLP0 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRPLP0
Nameribosomal protein, large, P0
Aliases PRLP0; L10E; RPP0; LP0; acidic ribosomal phosphoprotein P0; 60S ribosomal protein L10E; 60S acidic ribosomal ......
Chromosomal Location12q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RPLP0 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.